[Federal Register Volume 89, Number 74 (Tuesday, April 16, 2024)]
[Notices]
[Page 26926]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-07988]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Subcutaneous Drug Development & Delivery 
Consortium, Inc.

    Notice is hereby given that on February 2, 2024, pursuant to 
section 6(a) of the Act of the National Cooperative Research and 
Production Act of 1993, 15 U.S.C. 4301 et seq. (``the Act''), 
Subcutaneous Drug Development & Delivery Consortium, Inc. (``SC 
Consortium'') has filed written notifications simultaneously with the 
Attorney General and the Federal Trade Commission disclosing changes in 
its membership. The notifications were filed for the purpose of 
extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances. 
Specifically, Eli Lilly and Company, Indianapolis, IN; and 
Kal[eacute]o, Inc., Richmond, VA, have withdrawn as parties to this 
venture.
    No other changes have been made in the membership or the planned 
activity of the group research project. Membership in this group 
research project remains open and Subcutaneous Drug Development & 
Delivery Consortium, Inc. intends to file additional written 
notifications disclosing all changes in membership.
    On October 26, 2020, Subcutaneous Drug Development & Delivery 
Consortium, Inc. filed its original notification pursuant to section 
6(a) of the Act. The Department of Justice published a notice in the 
Federal Register pursuant to section 6(b) of the Act on December 3, 
2020 (85 FR 78148).
    The last notification was filed with the Department on June 23, 
2023. A notice was published in the Federal Register pursuant to 
section 6(b) of the Act on August 23, 2023 (88 FR 57479).

Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-07988 Filed 4-15-24; 8:45 am]
BILLING CODE P